Quality initiatives: MR imaging in patients at risk for developing nephrogenic systemic fibrosis: Protocols, practices, and imaging techniques to maximize patient safety

Radiographics

Volumn 29, Issue 1, 2009, Pages 9-22

  Juluru, Krishna ^a   Vogel Claussen, Jens ^b   Macura, Katarzyna J ^b   Kamel, Ihab R ^b   Steever, Alexander ^a   Bluemke, David A ^b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; DIAGNOSTIC AGENT; GADOLINIUM;

ARTICLE; CHEMICALLY INDUCED DISORDER; HUMAN; METHODOLOGY; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RISK ASSESSMENT; RISK FACTOR; SAFETY;

CONTRAST MEDIA; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY; RISK ASSESSMENT; RISK FACTORS; SAFETY MANAGEMENT;

EID: 63049106612     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.291085072     Document Type: Article

References (30)

1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356(9234):1000-1001.
2. Gibson SE, Farver CF, Prayson RA. Multiorgan involvement in nephrogenic fi brosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med 2006;130(2):209-212.
3. Grobner T. Gadolinium: a specifi c trigger for the development of nephrogenic fi brosing dermopathy and nephrogenic systemic fi brosis? Nephrol Dial Transplant 2006;21(4):1104-1108.
4. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fi brosis: why radiologists should be concerned. AJR Am J Roentgenol 2007;188(2): 586-592.
5. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fi brosis. J Am Acad Dermatol 2007;56(1):21-26.
6. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fi brosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17(9): 2359-2362.
7. Food and Drug Administration, United States. Information for healthcare professionals: gadoliniumbased contrast agents for magnetic resonance imaging (marketed as Magnevist, MultiHance, Omniscan, OptiMARK, ProHance)-5/23/2007. Available at: http://www.fda.gov/cder/drug/InfoSheets /HCP/gcca_200705.htm. Accessed November 7, 2007.
8. Food and Drug Administration, United States. Gadolinium-containing contrast agents for magnetic resonance imaging (MRI): Omniscan, OptiMARK, Magnevist, ProHance, and Multi-Hance-6/8/2006. Available at: http://www.fda.gov/cder/drug/advisory/gadolinium_agents.htm. Accessed November 8, 2007.
9. Food and Drug Administration, United States. Public health advisory: update on magnetic resonance imaging (MRI) contrast agents containing gadolinium and nephrogenic fi brosing dermopathy-12/22/2006. Available at: http://www.fda.gov/cder/drug/advisory/gadolinium_agents_20061222. htm. Accessed November 7, 2007.
10. Cowper SE. Nephrogenic fi brosing dermopathy (NFD/NSF website), 2001-2008. Available at: http://www.icnfdr.org/. Accessed March 8, 2008.
11. Cowper SE. Nephrogenic fi brosing dermopathy: the first 6 years. Curr Opin Rheumatol 2003;15(6): 785-790.
12. Jimenez SA, Artlett CM, Sandorfi N, et al. Dialysisassociated systemic fi brosis (nephrogenic fi brosing dermopathy): study of infl ammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 2004;50(8):2660-2666.
13. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fi brosing dermopathy. Am J Dermatopathol 2001;23(5):383-393.
14. Kucher C, Xu X, Pasha T, Elenitsas R. Histopathologic comparison of nephrogenic fi brosing dermopathy and scleromyxedema. J Cutan Pathol 2005; 32(7):484-490.
15. Mackay-Wiggan JM, Cohen DJ, Hardy MA, Knobler EH, Grossman ME. Nephrogenic fi brosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol 2003;48(1):55-60.
16. Schmitt-Willich H. Stability of linear and macrocyclic gadolinium based contrast agents. Br J Radiol 2007;80(955):581-582.
17. Lin SP, Brown JJ. MR contrast agents: physical and pharmacologic basics. J Magn Reson Imaging 2007; 25(5):884-899.
18. Omniscan (gadodiamide) injection [package insert]. Princeton, NJ: GE Healthcare, 2007.
19. Optimark (gadoversetamide) injection [package insert]. St Louis, Mo: Mallinckrodt, 2007.
20. Multihance (gadobenate dimeglumine) injection [package insert]. Princeton, NJ: Bracco Diagnostics, 2007.
21. Magnevist (gadopentetate dimeglumine) injection [package insert]. Wayne, NJ: Bayer Healthcare Pharmaceuticals, 2007.
22. Hamm B, Staks T, Muhler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995;195(3):785-792.
23. Shamsi K, Yucel EK, Chamberlin P. A summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: Phase II and Phase III clinical trials data. Invest Radiol 2006;41(11):822-830.
24. Prohance (gadoteridol) injection [package insert]. Princeton, NJ: Bracco Diagnostics, 2007.
25. Laurent S, Elst LV, Muller RN. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging 2006;1(3):128-137.
26. Gadovist (gadobutrol) injection [package insert]. Berlin, Germany: Bayer, 2007.
27. Saitoh T, Hayasaka K, Tanaka Y, Kuno T, Nagura Y. Dialyzability of gadodiamide in hemodialysis patients. Radiat Med 2006;24(6):445-451.
28. Dorsam J, Knopp MV, Schad L, Piesche S, Carl S, Oesingmann N. Elimination of gadolinium-DTPA by peritoneal dialysis. Nephrol Dial Transplant 1995;10(7):1228-1230.
29. Lockhart ME, Smith JK, Kenney PJ. Imaging of adrenal masses. Eur J Radiol 2002;41(2):95-112.
30. Laub G. Basic principles of MR angiography: an introduction [in German]. Radiologe 1994;34(8): 416-422.